AKT isoform-specific expression and activation across cancer lineages

[1]  Lynette M. Smith,et al.  Role of Akt2 in regulation of metastasis suppressor 1 expression and colorectal cancer metastasis , 2017, Oncogene.

[2]  J. Baselga,et al.  A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. , 2017, Cancer discovery.

[3]  J. Cheng,et al.  pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner , 2016, Science.

[4]  L. Magnani,et al.  Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer. , 2016, Cancer research.

[5]  Ken Chen,et al.  Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations. , 2015, Cancer research.

[6]  P. Timpson,et al.  The Inositol Polyphosphate 5-Phosphatase PIPP Regulates AKT1-Dependent Breast Cancer Growth and Metastasis. , 2015, Cancer cell.

[7]  J. Clohessy,et al.  In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes. , 2015, Cancer discovery.

[8]  M. Nykter,et al.  Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression , 2015, Proceedings of the National Academy of Sciences.

[9]  A. Toker,et al.  Signalling specificity in the Akt pathway in breast cancer. , 2014, Biochemical Society transactions.

[10]  G. Mills,et al.  Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules , 2014, Oncogene.

[11]  A. Toker,et al.  PTEN-deficient tumors depend on AKT2 for maintenance and survival. , 2014, Cancer discovery.

[12]  A. Toker,et al.  Signaling specificity in the Akt pathway in biology and disease. , 2014, Advances in biological regulation.

[13]  Andrew H. Beck,et al.  Targeting Akt3 signaling in triple-negative breast cancer. , 2014, Cancer research.

[14]  A. Tolcher,et al.  Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors , 2014, Journal of Hematology & Oncology.

[15]  Anandita Rajpurohit,et al.  PIK3CA and AKT1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System , 2013, Clinical Cancer Research.

[16]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[17]  A. Sivachenko,et al.  Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.

[18]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[19]  A. Toker.  Achieving specificity in Akt signaling in cancer. , 2012, Advances in biological regulation.

[20]  David Olmos,et al.  First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Ellison,et al.  Nonredundant functions for Akt isoforms in astrocyte growth and gliomagenesis in an orthotopic transplantation model. , 2011, Cancer research.

[22]  A. Toker,et al.  The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration. , 2010, Molecular cell.

[23]  G. Mills,et al.  Physical Association of PDK1 with AKT1 Is Sufficient for Pathway Activation Independent of Membrane Localization and Phosphatidylinositol 3 Kinase , 2010, PloS one.

[24]  K. Kinzler,et al.  Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation , 2010, Proceedings of the National Academy of Sciences.

[25]  G. Mills,et al.  Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. , 2009, Cancer research.

[26]  B. Park,et al.  Knockin of mutant PIK3CA activates multiple oncogenic pathways , 2009, Proceedings of the National Academy of Sciences.

[27]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[28]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[29]  Hong Liu,et al.  Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Brugge,et al.  Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial–mesenchymal transition , 2005, The Journal of cell biology.

[31]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[32]  J. Engelman,et al.  Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. , 2005, Cancer research.

[33]  Carlo Rago,et al.  Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.

[34]  P. Vogt,et al.  Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[35]  B. Hemmings,et al.  Advances in protein kinase B signalling: AKTion on multiple fronts. , 2004, Trends in biochemical sciences.

[36]  Robert D Cardiff,et al.  Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. , 2004, Cancer research.

[37]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[38]  G. Mills,et al.  The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. , 2001, Seminars in oncology.

[39]  B. Hemmings,et al.  A Human Protein Kinase Bγ with Regulatory Phosphorylation Sites in the Activation Loop and in the C-terminal Hydrophobic Domain* , 1999, The Journal of Biological Chemistry.

[40]  R. Roth,et al.  Akt, a Pleckstrin Homology Domain Containing Kinase, Is Activated Primarily by Phosphorylation* , 1996, The Journal of Biological Chemistry.

[41]  J. Cheng,et al.  Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Cheng,et al.  Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas , 1995, International journal of cancer.